Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.

Cancer chemotherapy and pharmacology - 1 Aug 2016

Mizoguchi Kosuke, Nakamura Yoichi, Sano Kazumi, Sato Shuntaro, Ikegami Yoji, Motoshima Kohei, Takemoto Shinnosuke, Ogawara Daiki, Senju Hiroaki, Sugasaki Nanae, Ikeda Takaya, Yamaguchi Hiroyuki, Nakatomi Katsumi, Fukuda Minoru, Izumikawa Koichi, Mukae Hiroshi

Abstract excerpt

PURPOSE: The relationship between plasma concentration and antitumor activity of gefitinib was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. PATIENTS AND METHODS: Plasma trough levels of gefitinib were measured on days 2 (D2) and 8 (D8) by high-performance liquid chromatography in 31 patients. Plasma concentrations of gefitinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Chromatography, High Pressure Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to ErbB Receptors

Share to Gefitinib

Share to Half-Life

Share to Quinazolines

Share to Survival Rate

Source

Identifiers

PMID: 27339148
DOI: 10.1007/s00280-016-3097-4

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.PMID 27339148Read ↗

Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.Semantic proximity Read ↗

Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.Semantic proximity Read ↗

The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation.Semantic proximity Read ↗

Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics.Semantic proximity Read ↗

Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.Semantic proximity Read ↗

Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.Semantic proximity Read ↗

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations.Semantic proximity Read ↗

Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations.Semantic proximity Read ↗

Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients.Semantic proximity Read ↗

Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer.Semantic proximity Read ↗

Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib.Semantic proximity Read ↗

Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.